MedPath
HSA Product

NOLVADEX TABLET 10 mg

Product approved by Health Sciences Authority (SG)

Basic Information

NOLVADEX TABLET 10 mg

TABLET, FILM COATED

Regulatory Information

SIN00794P

May 6, 1988

Prescription Only

Therapeutic

ORAL

August 10, 2023

May 30, 2025

XL02BA01

Company Information

ASTRAZENECA UK LTD

ASTRAZENECA SINGAPORE PTE LTD

ASTRAZENECA SINGAPORE PTE LTD

Active Ingredients

Detailed Information

Contraindications

**4.3 Contraindications** **_Pregnancy:_** NOLVADEX must not be given during pregnancy. Premenopausal patients must be carefully examined before treatment to exclude the possibility of pregnancy (see also Pregnancy and lactation – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). NOLVADEX should not be given to patients who have experienced hypersensitivity to the product or any of its ingredients.

Indication Information

**4.1 Therapeutic indication** NOLVADEX is indicated for the treatment of breast cancer.

© Copyright 2025. All Rights Reserved by MedPath